More PEOPLE More OFTEN ON More DIVERSE AND INTRIGUING TOPICS.
Space commitment: May 12, 2006 Material Due: May 19 , 2006
R&D TOPIC: Taking it to the Board — Institutional Review Boards (IRBs) are an important piece of the clinical puzzle. IRBs are the gatekeepers of ethical, regulatory, and policy concerns of human-subject research. Learn what the leaders in this sector of the industry have to say about the impact of HIPAA, patients' rights, and clinical good practices.
Marketing TOPIC: The Internet — Surfing at its Best — Industry experts discuss best practices for developing comprehensive search engine optimization strategies for pharmaceutical brand Websites, which is particularly important as marketing makes the move toward more patient-centric communications.
Therapeutic CATEGORY: Orphan Drugs — Small patient populations, but important clinical and market opportunities. The Office of Orphan Products Development (OOPD) has successfully brought more than 200 drugs and biological products for rare diseases to market since 1983. Experts discuss the challenges and rewards of this sector of the industry.
Industry BIO: Theresa Kane Musser — Theresa Kane Musser is Acting President of the Drug Information Association and Executive Director of Development Operations at Rigel Pharmaceuticals Inc.
For Bonus Distribution for the April issue please
“Your Agenda is our Agenda”
For advertising, call (609)730-0196 to speak with Lisa Banket, Publisher (firstname.lastname@example.org), or contact Melissa Drozdoff (908)638-5730 (email@example.com), or Cathy Tracy (203)778-1463, (firstname.lastname@example.org).
*Editorial content is subject to change.
Read. Think. Participate.
This email is CAN-SPAM compliant. If you do not wish to receive PharmaVOICE advertising announcements and updates, please send email to email@example.com and type UNSUBSCRIBE ALERT in the subject line. If the "Unsubscribe" link is not working, please "Forward" this email to firstname.lastname@example.org to be removed from future mailings or please send a letter including your name, request for removal, and email address to: PharmaVOICE, PO Box 327, Titusville, NJ 08560